EGCG was initially identified as a candidate therapeutic treatment for Down syndrome (DS) phenotypes based largely on the in vitro demonstration that EGCG inhibits Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) activity8,9. The gene discussed is DYRK1A; the disease is Dravet syndrome.